Advanced therapies for inflammatory bowel disease associated with primary sclerosing cholangitis: a systematic review and meta-analysis
{{output}}
Background and aims: Up to 70%-80% of patients with primary sclerosing cholangitis (PSC) will have concomitant inflammatory bowel disease (IBD). Scarce data are available regarding outcomes of advanced therapies to treat IBD-PSC.... ...
